At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 99 enrolled
Drug / intervention
Temozolomide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
In Brief
A Phase 4 clinical trial evaluating Temozolomide and Radiotherapy for Glioblastoma. Completed, enrolled 99 participants.
Detailed Summary
The primary purpose of the study is to evaluate the efficacy and safety of early postsurgery temozolomide chemotherapy followed by the standard temozolomide regimen, compared to the standard regimen alone, for the treatment of patients with newly diagnosed glioblastoma multiforme.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJun 2008
Primary CompletionSep 2011
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartJun 24, 2008
Primary CompletionSep 28, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.1 years ago
Interventions
Temozolomidedrug
Radiotherapyradiation